絞り込み

16645

広告

「頑張っている薬剤師への評価を」 (日経BP)

2020年1月24日、中央社会保険医療協議会(中医協)総会は、公聴会を開催した。公聴会は、中医協委員が広く国民の声を聞くために開催しており、今回は静岡県富士市の...

  1. 薬剤師国試の合否を分ける科目とは? (日...
  2. 臨床検査値を活用するのはどんな場面? (...
  3. [企業] AbbVieによる買収を成立さ...
  4. バッファローとバイソン、チョウとガ、どう...

ニュース一覧

スターを付ける スターを付ける     (4view , 0users)

Full Text Sources

The composition of the lung microbiome is increasingly well characterised, with changes in microbial diversity or abundance observed in association with several chronic respiratory diseases such as asthma, cystic fibrosis, bronchiectasis, and chronic obstructive pulmonary disease. However, the precise effects of the microbiome on pulmonary health and the functional mechanisms by which it regulates host immunity are only now beginning to be elucidated. Bacteria, viruses, and fungi from both the upper and lower respiratory tract produce structural ligands and metabolites that interact with the host and alter the development and progression of chronic respiratory diseases. Here, we review recent advances in our understanding of the composition of the lung microbiome, including the virome and mycobiome, the mechanisms by which these microbes interact with host immunity, and their functional effects on the pathogenesis, exacerbations, and comorbidities of chronic respiratory diseases. We also describe the present understanding of how respiratory microbiota can influence the efficacy of common therapies for chronic respiratory disease, and the potential of manipulation of the microbiome as a therapeutic strategy. Finally, we highlight some of the limitations in the field and propose how these could be addressed in future research.
PMID: 30975495 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード